Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: Systematic review and meta-analysis

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 29, Issue 7, 2010, Pages 779-786

  Chowers, M ^a,b   Gottesman, B S ^a,b   Leibovici, L ^a,c   Schapiro, J M ^d   Paul, M ^a,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS DIDANOSINE; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIVIRUS AGENT; DIDANOSINE PLUS EMTRICITABINE; DIDANOSINE PLUS EMTRICITABINE PLUS LAMIVUDINE; DIDANOSINE PLUS LAMIVUDINE; DIDANOSINE PLUS STAVUDINE; EMTRICITABINE PLUS LAMIVUDINE PLUS TENOFOVIR; EMTRICITABINE PLUS TENOFOVIR; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS TENOFOVIR; LAMIVUDINE PLUS ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NUCLEOSIDE; RNA DIRECTED DNA POLYMERASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; ADOLESCENT; ADULT; AGED; ANTAGONISTS AND INHIBITORS; HIV INFECTIONS; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HUMANS; MIDDLE AGED; NUCLEOSIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 77955418914     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-010-0926-y     Document Type: Review

References (40)

1. DL Paterson S Swindells J Mohr M Brester EN Vergis C Squier MM Wagener N Singh 2000 Adherence to protease inhibitor therapy and outcomes in patients with HIV infection Ann Intern Med 133 1 21 30 1:STN:280:DC%2BD3czit1altA%3D%3D 10877736
2. Panel on Antiretroviral Guidelines for Adults and Adolescents (2008) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available online at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Cited May 2009
3. N Clumeck A Pozniak F Raffi 2008 European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults HIV Med 9 2 65 71 10.1111/j.1468-1293.2007.00533.x 1:STN:280:DC%2BD1c3gsFSnsw%3D%3D 18257769 (Pubitemid 351228129)
4. JA Bartlett MJ Fath R Demasi A Hermes J Quinn E Mondou F Rousseau 2006 An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults AIDS 20 16 2051 2064 10.1097/01.aids.0000247578.08449.ff 1:CAS:528:DC%2BD28XhtV2rsrnF 17053351 (Pubitemid 44611058)
5. Higgins JPT, Green S (eds) Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Appendix 5b. In: The Cochrane Library, Issue 3, 2005. John Wiley & Sons, Ltd., Chichester, UK
6. JP Higgins SG Thompson JJ Deeks DG Altman 2003 Measuring inconsistency in meta-analyses BMJ 327 7414 557 560 10.1136/bmj.327.7414.557 12958120
7. Berenguer J, González J, Ribera E, Domingo P, Mirales P, Ribas MA, Asensi V, Gimeno JL, Terrón JA, Pérez Molina JA (2007) Didanosine, lamivudine and efavirenz vs zidovudine, lamivudine and efavirenz, for initial treatment of HIV infection over 48 weeks: a randomized non-inferiority clinical trial, GESIDA 3903. ICAAC, Chicago, IL
8. F Maggiolo D Ripamonti G Gregis G Quinzan A Callegaro C Arici L Ravasio F Suter 2003 Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients Antivir Ther 8 4 339 346 1:CAS:528:DC%2BD3sXnvFyht7w%3D 14518703
9. MS Saag P Cahn F Raffi M Wolff D Pearce JM Molina W Powderly AL Shaw E Mondou J Hinkle K Borroto-Esoda JB Quinn DW Barry F Rousseau 2004 Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial JAMA 292 2 180 189 10.1001/jama.292.2.180 1:CAS:528:DC%2BD2cXlvVSnsbw%3D 15249567 (Pubitemid 38917995)
10. Maggiolo F, Ripamonti D, Migliorino G, Martinelli C, Sighinolfi L, Quinzan G, Gregis G, Abeli C, Airold i M, Suter F (2006) Comparison of three once-a-day regimens as first-line HAART. In Proceedings of the AIDS 2006-XVI International AIDS Conference, Toronto, Canada, August 2006
11. JR Arribas AL Pozniak JE Gallant E Dejesus B Gazzard RE Campo SS Chen D McColl CB Holmes J Enejosa JJ Toole AK Cheng 2008 Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis J Acquir Immune Defic Syndr 47 1 74 78 10.1097/QAI.0b013e31815acab8 1:CAS:528:DC%2BD2sXhsVGgur7N 17971715 (Pubitemid 351619372)
12. JE Gallant E DeJesus JR Arribas AL Pozniak B Gazzard RE Campo B Lu D McColl S Chuck J Enejosa JJ Toole AK Cheng 2006 Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV N Engl J Med 354 3 251 260 10.1056/NEJMoa051871 1:CAS:528:DC%2BD28Xls1Grsg%3D%3D 16421366 (Pubitemid 43113030)
13. JE Gallant S Staszewski AL Pozniak E DeJesus JM Suleiman MD Miller DF Coakley B Lu JJ Toole AK Cheng 2004 Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial JAMA 292 2 191 201 10.1001/jama.292.2.191 1:CAS:528: DC%2BD2cXlvVSnur0%3D 15249568 (Pubitemid 38917996)
14. Sax P, Tierney C, Collier A, Fischl M, Godfrey C, Jahed N, Droll K, Peeples L, Myers L, Thal G, Rooney J, Ha B, Woodward W, Daar E (2008) ACTG 5202: shorter time to virologic failure (VF) with abacavir/lamivudine (ABC/3TC) than tenofovir/emtricitabine (TDF/FTC) as part of combination therapy in treatment-naïve subjects with screening HIV RNA 100,000 c/mL. In: Proceedings of the AIDS 2008-XVII International AIDS Conference, Mexico City, August 2008
15. Smith K, Fine D, Patel P, Bellos N, Sloan L, Lackey P, Sutherland-Phillips D, Vavro C, Liao Q, Shaefer M (2008) Efficacy and safety of abacavir/lamivudine compared to tenofovir/emtricitabine in combination with once-daily lopinavir/ritonavir through 48 weeks in the HEAT study. In: Proceedings of the 15th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, February 2008
16. E DeJesus G Herrera E Teofilo J Gerstoft CB Buendia JD Brand CH Brothers J Hernandez SA Castillo T Bonny ER Lanier TR Scott 2004 Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults Clin Infect Dis 39 7 1038 1046 10.1086/424009 1:CAS:528:DC%2BD2cXptFKjs7g%3D 15472858 (Pubitemid 39313463)
17. D Podzamczer E Ferrer P Sanchez JM Gatell M Crespo C Fisac M Lonca J Sanz J Niubo S Veloso JM Llibre P Barrufet MA Ribas E Merino E Ribera J Martínez-Lacasa C Alonso M Aranda F Pulido J Berenguer A Delegido JD Pedreira A Lérida R Rubio L del Río 2007 Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study J Acquir Immune Defic Syndr 44 2 139 147 10.1097/QAI. 0b013e31802bf122 1:CAS:528:DC%2BD2sXitVehu74%3D 17106274 (Pubitemid 46292215)
18. RD MacArthur L Chen G Peng RM Novak M Van Den Berg-Wolf M Kozal L Besch T Yurik B Schmetter C Henley M Dehlinger 2004 Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons HIV Clin Trials 5 6 361 370 10.1310/WEQG-QTHL-DL3X-FTXC 1:STN:280:DC%2BD2M%2Flt1yjuw%3D%3D 15682349 (Pubitemid 40253636)
19. A Carr J Chuah J Hudson M French J Hoy M Law D Sayer S Emery DA Cooper 2000 A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study AIDS 14 9 1171 1180 10.1097/00002030-200006160-00014 1:CAS:528:DC%2BD3cXltFWmsr0%3D 10894281 (Pubitemid 30420660)
20. Domula MR, Wasmuth JC, Jütte A, Fätkenheuer G, Oette M, Theisen A, Höhn C, Knechten H, Pfeil B, Fenske S, Rieke A, Rockstroh JK (2002) A comparison of AZT/3TC vs 3TC/d4T and ddI/d4T in combination with efavirenz as first line therapy: efficacy and safety results after 48 weeks. In: Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA, February 2002
21. PN Kumar A Rodriguez-French MA Thompson KT Tashima D Averitt PG Wannamaker VC Williams MS Shaefer GE Pakes KA Pappa 2006 A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/ nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity HIV Med 7 2 85 98 10.1111/j.1468-1293. 2006.00346.x 1:CAS:528:DC%2BD28Xis1yjsbg%3D 16420253
22. KE Squires R Gulick P Tebas J Santana V Mulanovich R Clark B Yangco SI Marlowe D Wright C Cohen T Cooley J Mauney K Uffelman N Schoellkopf R Grosso M Stevens 2000 A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I) AIDS 14 11 1591 1600 10.1097/00002030-200007280-00015 1:CAS:528:DC%2BD3cXmslWnsbs%3D 10983646
23. M French J Amin N Roth A Carr M Law S Emery F Drummond D Cooper 2002 Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study HIV Clin Trials 3 3 177 185 10.1310/9N21-1HG1-7N1Q-JKW1 12032876
24. Antela A, Iribarren JA, Mahillo B, Santos I, Ribera E, Gutierrez C, Esteban H, Labarga P, González J, Andia A, Marti-Belda P (2004) Final analysis of a prospective, randomized, open-label, multicenter trial in naive, HIV-1-infected patients, comparing ZDV/3TC vs d4T/ddI, plus Efavirenz, Nevirapine or Indinavir/Ritonavir (AMADEUS 01 study). In: Proceedings of the XV International AIDS Conference, Bangkok, Thailand, July 2004
25. JJ Eron ES Yetzer PJ Ruane S Becker GA Sawyer RL Fisher JM Tolson MS Shaefer 2000 Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection AIDS 14 6 671 681 10.1097/00002030-200004140-00006 1:CAS:528:DC%2BD3cXjtlKlt78%3D 10807190 (Pubitemid 30229346)
26. J Gathe Jr R Badaro A Grimwood L Abrams K Klesczewski A Cross C McLaren 2002 Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir J Acquir Immune Defic Syndr 31 4 399 403 1:CAS:528:DC%2BD38XovFSitrY%3D 12447010
27. RW Shafer LM Smeaton GK Robbins V De Gruttola SW Snyder RT D'Aquila VA Johnson GD Morse MA Nokta AI Martinez BM Gripshover P Kaul R Haubrich M Swingle SD McCarty S Vella MS Hirsch TC Merigan 2003 Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection N Engl J Med 349 24 2304 2315 10.1056/NEJMoa030265 1:CAS:528:DC%2BD3sXpvVChur4%3D 14668456 (Pubitemid 37509738)
28. J Berenguer J González E Ribera P Domingo J Santos P Miralles M Angels Ribas V Asensi JL Gimeno JA Pérez-Molina JA Terrón JM Santamaría E Pedrol 2008 Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903 Clin Infect Dis 47 8 1083 1092 10.1086/592114 1:CAS:528:DC%2BD1cXhtlSru7nL 18781872
29. RM Gulick HJ Ribaudo CM Shikuma C Lalama BR Schackman WA Meyer 3rd EP Acosta J Schouten KE Squires CD Pilcher RL Murphy SL Koletar M Carlson RC Reichman B Bastow KL Klingman DR Kuritzkes 2006 Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial JAMA 296 7 769 781 10.1001/jama.296.7.769 1:CAS:528:DC%2BD28XosVWms70%3D 16905783 (Pubitemid 44223101)
30. C Orkin J Stebbing M Nelson M Bower M Johnson S Mandalia R Jones G Moyle M Fisher B Gazzard 2005 A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study) J Antimicrob Chemother 55 2 246 251 10.1093/jac/dkh515 1:CAS:528:DC%2BD2MXovVyrsQ%3D%3D 15608053 (Pubitemid 40331153)
31. A Carr 2002 Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy Lancet 360 9326 81 85 10.1016/S0140-6736(02)09341-8 12114062 (Pubitemid 34756501)
32. JJ Eron Jr RL Murphy D Peterson J Pottage DM Parenti J Jemsek S Swindells G Sepulveda N Bellos BC Rashbaum J Esinhart N Schoellkopf R Grosso M Stevens 2000 A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II) AIDS 14 11 1601 1610 10.1097/00002030-200007280-00016 1:CAS:528:DC%2BD3cXmslWnsbk%3D 10983647
33. CA Sabin SW Worm R Weber P Reiss W El-Sadr F Dabis S De Wit M Law A D'Arminio Monforte N Friis-Møller O Kirk C Pradier I Weller AN Phillips JD Lundgren 2008 Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration Lancet 371 9622 1417 1426 10.1016/S0140-6736(08) 60423-7 1:CAS:528:DC%2BD1cXlsFCisL8%3D 18387667
34. K Boubaker M Flepp P Sudre H Furrer A Haensel B Hirschel K Boggian JP Chave E Bernasconi M Egger M Opravil M Rickenbach P Francioli A Telenti 2001 Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study Clin Infect Dis 33 11 1931 1937 10.1086/324353 1:CAS:528:DC%2BD3MXpt1KjtL8%3D 11692306 (Pubitemid 33105136)
35. G Dragovic N Milic DJ Jevtovic 2005 Incidence of acute pancreatitis and nucleoside reverse transcriptase inhibitors usage Int J STD AIDS 16 6 427 429 10.1258/0956462054094042 1:STN:280:DC%2BD2MzitFektw%3D%3D 15969777 (Pubitemid 40868379)
36. JJ Guo R Jang A Louder RJ Cluxton 2005 Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus Pharmacotherapy 25 8 1044 1054 10.1592/phco.2005.25.8. 1044 16207094 (Pubitemid 41099438)
37. CJ Smith A Mocroft JD Lundgren 2008 Incidence of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy AIDS 22 8 997 998 10.1097/QAD.0b013e3282ffb0fd 18453864 (Pubitemid 351652255)
38. KA Lichtenstein C Armon A Baron AC Moorman KC Wood SD Holmberg 2005 Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort Clin Infect Dis 40 1 148 157 10.1086/426076 15614705 (Pubitemid 40053473)
39. A Carr J Amin 2009 Efficacy and tolerability of initial antiretroviral therapy: a systematic review AIDS 23 3 343 353 10.1097/QAD.0b013e32831db232 19114855 discussion 355-346
40. Strategies for Management of Anti-Retroviral Therapy/INSIGHT DAD Study Groups 2008 Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients AIDS 22 14 F17 F24 10.1097/QAD.0b013e32830fe35e